GoldenGolden
Advanced Search
Kite Pharma

Kite Pharma

A company focused on delivering cure for cancer using engineered T cell therapy

Gilead Sciences and Kite Pharma acquired Cell Design Labs in 2017. synNotch technology was developed in the lab of Wendell Lim at UC San Francisco and further developed by Cell Design Labs, to rewire immune cells and create customized cells that can carry out highly specialized actions in the body. synNotch technology can be applied to therapeutics for cancer, autoimmune and infectious diseases. A collaboration between Kite's parent company, Gilead and Kyverna aims to treat autoimmune disease using Kyverna’s Treg platform and Kite’s synNotch technology.

Timeline

May 2013
Kite Pharma raises a $15,000,000 series A round from Alta Partners, Commercial Street Capital, David Bonderman, Michael Milken and Pontifax Venture Capital.
December 20, 2012
Kite Pharma raises a $250,000 seed round.
March 9, 2011
Kite Pharma raises a $15,000,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Adam Smith

Founder

Alexandra Stanley

Employee

Amit Patel

Investor

Andy Park

Employee

Brendan McDonnell

Employee

Brian Jackson

Employee

Caelan Urquhart

Employee

Cara Debbaudt

Employee

Dane Bratz

Employee

Daniel Hung

Employee

Debra Susarchick

Employee

Devan Zappia

Employee

Drew Houston

Investor

Emmett Shear

Investor

Kyle Vogt

Investor

Lee Linden

Advisor

Linsey Fisher

Employee

Liza Jardiolin

Employee

Mario de Vera

Employee

Max Levchin

Investor

Oliver Valle

Employee

Reddy Kal

Employee

Robert Castellanos

Employee

Robert Crater

Employee

Robert T Chang

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
June 21, 2021
BioSpace
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
Amirah Al Idrus
June 18, 2021
FierceBiotech
Gilead's Kite unit made its name developing autologous CAR-T treatments made from a patient's own cells. Now, the subsidiary is making another big play in off-the-shelf treatments that can be developed more quickly in a deal with Shoreline Biosciences that could exceed $2.3 billion. The partners will initially work on CAR targets for natural killer cell therapies for blood cancers.
June 10, 2021
BioSpace
ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company's Immunotherapy Platform Expansion - read this article along with other careers information, tips and advice on BioSpace
Amirah Al Idrus
May 26, 2021
FierceBiotech
Brent Pfeiffenberger grew up at Bristol Myers Squibb, developing as a leader over a nearly 19-year tenure at the Big Pharma. Now, he's taking his experience into the biotech world as the chief operating officer of Neogene Therapeutics, a transatlantic biotech working on next-generation T-cell therapies.
Research and Markets
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "CAR-T Therapy Pipeline Analysis Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets....
Heather McKenzie
May 11, 2021
BioSpace
Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
Amirah Al Idrus
May 10, 2021
FierceBiotech
Appia Bio launches with $52 million to develop off-the-shelf cell therapies for cancer based on hematopoietic, or blood-forming, stem cells. Its platform, dubbed ACUA, allows for the programming of stem cells to become invariant natural killer T (iNKT) cells, a rare but powerful subtype of T cell. The company hopes to be in the clinic in 2023.
May 5, 2021
BioSpace
Century Therapeutics Expands Board of Directors with Key Appointments - read this article along with other careers information, tips and advice on BioSpace
Amirah Al Idrus
February 8, 2021
FierceBiotech
After a quick pit stop at Verastem Oncology, Frank Neumann, M.D., Ph.D. has landed at Gilead's Kite Pharma, where he will lead clinical development in blood cancers and solid tumors. His move follows a two-week tenure as Verastem,s chief medical officer, a post he left to work on cell therapy R&D.
BioSpace
November 18, 2020
BioSpace
4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors.
Alex Keown
November 6, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
May 29, 2020
BioSpace
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.